SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer

SA-4-1BBL and Monophosphoryl Lipid A Constitute an Efficacious Combination Adjuvant for Cancer Vaccines

(2014) A. K. Srivastava et al.   CANCER RESEARCH

SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines

(2014) Rajesh K Sharma et al.   Expert Review of Vaccines

CD4+ T Cells Play a Critical Role in the Generation of Primary and Memory Antitumor Immune Responses Elicited by SA-4-1BBL and TAA-Based Vaccines in Mouse Tumor Models

(2013) Rajesh K. Sharma et al.   PLoS One

SA-4-1BBL Costimulation Inhibits Conversion of Conventional CD4+ T Cells into CD4+FoxP3+ T Regulatory Cells by Production of IFN-γ

(2012) Shravan Madireddi et al.   PLoS One

Prime-Boost Vaccination with SA-4-1BBL Costimulatory Molecule and Survivin Eradicates Lung Carcinoma in CD8+ T and NK Cell Dependent Manner

(2012) Abhishek K. Srivastava et al.   PLoS One

4-1BB Ligand as an Effective Multifunctional Immunomodulator and Antigen Delivery Vehicle for the Development of Therapeutic Cancer Vaccines

(2010) R. K. Sharma et al.   CANCER RESEARCH

Costimulation as a Platform for the Development of Vaccines: A Peptide-Based Vaccine Containing a Novel Form of 4-1BB Ligand Eradicates Established Tumors

(2009) R. K. Sharma et al.   CANCER RESEARCH